BioSpace News Archive

The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.

For patients with epilepsy, the diagnosis and treatment process can be long, arduous, and filled with lengthy hospital stays. The medical device company NeuroOne Medical Technologies Corporation hopes to change that.

The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.

Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).

The U.S. government is putting together the infrastructure for widespread distribution of a COVID-19 vaccine, if and when one is granted emergency use authorization (EUA) or full approval.

Results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.

The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present an update on Company progress at two upcoming conferences in September using a virtual platform. H.C. Wainwright 22 nd Annual Global Investment Conference on September 14, 2020 at 12:30pm

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced a successful Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment w